Farmacosmo S p A : The Board Of Directors Approves The Appointment By Co-Option Of A New Independent Director

PRESS RELEASE

THE BOARD OF DIRECTORS APPROVES

THE APPOINTMENT BY CO-OPTION OF A NEW

INDEPENDENT DIRECTOR

WITH THE ENTRANCE OF DOROTY DE RUBEIS,

FARMACOSMO'S BOARD OF DIRECTORS OBTAINS AN

INDEPENDENT MAJORITY

THE BOARD OF DIRECTORS ALSO APPROVES THE ADOPTION OF MODEL

231/2001 AND OF THE CODE OF CONDUCT

APPOINTMENT OF THE SUPERVISORY BODY

Naples, December 29th 2022

Farmacosmo S.p.A. ("Company", "Farmacosmo"), a company active in the Health, Pharma & Beauty sector, listed on the Euronext Growth Milan market of Borsa Italiana, announces that on today's day the Board of Directors approved the appointment by co-optation of the lawyer Doroty de Rubeis as the company's independent director.

As a result of the above, the Board of Directors is composed as follows:

• Fabio de Concilio: Chairman and Chief Executive Officer
• Alessandro Maiello: Director
• Giuseppe Vita: Independent Director1
• Maurizio Altini: Independent Director1
• Doroty de Rubeis: Independent Director

As an independent director, Mrs. de Rubeis will automatically join the Committee of Transactions with Related Parties, in accordance with the Company's Procedure for Transactions with Related Parties.

Doroty de Rubeis currently holds the position of General Counsel for Mediocredito Centrale S.p.A. During her career, she has held senior positions in the legal field, boasting more than twenty years of experience with a particular focus on the banking world. Her legal competences will grant Farmacosmo an additional value regarding both the operating of the Board of Directors and future M&A operations.

Fabio de Concilio, President and CEO of Farmacosmo declared: "With the entrance of the lawyer Doroty de Rubeis, the board of Farmacosmo acquires further experience, professionalism and competences which will actively contribute to the growth of the Company. With the appointment of the lawyer de Rubeis, Farmacosmo's Board of Directors obtains an independent majority, a rarity in the environment of the Euronext Growth Milan market, confirming the strong propensity of the Company to acquire highly professional figures with proven experience."

Adoption of Model 231/2001 and of the Code of Conduct and appointment of the Supervisory Body

The Board of Directors has approved the adoption of the "Model of Organisation, Management and Control" prepared pursuant to Legislative Decree no. 231/2001 (in short, "Model 231"), and the Code of Conduct. In compliance with the

1 Independent Director on which Euronext Growth Advisor gave its favourable opinion on 23 March 2022.

PRESS RELEASE

provisions of Model 231, the Board has also appointed the Supervisory Body which will have a duration of three years starting from today's date, consisting of three members all external to the Company, with the task of supervising the correct implementation, effectiveness and observance of Model 231 within the Company, as well as to see to its relative updates. The approval of Model 231 and the Code of Conduct allow the Company to strengthen its system of internal control and governance, in order to protect all stakeholders.

Model 231 and the Code of Conduct are available on the website www.farmacosmoinvestors.com, Governance/Documents section.

***

This press release is available on the www.farmacosmoinvestors.comwebsite, section "Investors/Press Releases" and on the authorized storage mechanism "eMarket Storage" (www.emarketstorage.com)."

***

THE SOCIETY

Farmacosmo is a company active in the Health, Pharma & Beauty sectors. The company's business model is based on the circular model of the l(ea)n strategy, and is divided into three main business areas: Logistics, Intelligence and Node. Logistics: enables the management and fulfilment of up to 12,000 orders per day, with delivery times of up to 20 hours from carrier picking and just-intime procurement ('zero warehouse' policy). Intelligence: includes strategy definition, competitive positioning and customer journey activities, which enabled the company to intercept c. 188,000 customers in 2021. Recurring customers contributed 74% of the annual retail stream turnover. The average cart value of active customers in the retail stream amounted to €92 (€109 related to recurring customers). Node: R&D activities, process innovation and IT infrastructure of the company. Over the past five years, Farmacosmo's sales value has grown by 54% (CAGR 2016-2021) and will be around €58 million in 2021. The Farmacosmo ecosystem aims to pursue standards of excellence in every part of its value chain, being inspired by compliance with ESG principles at all stages of the logistics process (from the packaging used for online orders to carbon compensation initiatives) and in the valorisation of its employees, the company's strategic asset. Farmacosmo's commitment to ESG is also underlined by the publication of its Sustainability Report 2021.

IDENTIFICATION CODES

Ordinary Shares: ISIN IT0005487670 (Ticker COSMO)

Warrant Farmacosmo 2022-2025: ISIN IT0005487415 (Ticker WCOSMO)

FOR FURTHER INFORMATION:
INVESTOR RELATIONS MANAGER	EURONEXT GROWTH ADVISOR	INVESTOR & MEDIA RELATIONS ADVISOR
Farmacosmo	Illimity Bank	IR Top Consulting
Via Crispi, 51 - 80121 Naples	Via Soperga, 9 - 20124 Milan	Via Bigli, 19 - 20121 Milan
Tel. [phone]	Tel. [phone]	Tel. [phone]
Paolo [e-mail]	[e-mail]	Pietro Autelitano [e-mail]
		Domenico [e-mail]